S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

SIBIONICS Debuts GS3 Glucose Monitor at Melbourne Medical Congress

At the 2026 IDF-WPR and Metabolic Diseases congress in Melbourne, SIBIONICS introduced the GS3, a 14-day continuous glucose monitor. The device leverages AI to refine meal logging and trend analysis, marking a shift from basic data tracking toward predictive, personalized support for patients managing diabetes and metabolic conditions.

SIBIONICS Debuts GS3 Glucose Monitor at Melbourne Medical Congress
Photo: Bio & News

The GS3 sensor arrives with a 2.9 mm profile, a design born from the company’s high-stakes research into retinal prosthetics for degenerative vision loss. By adapting this biosensing platform for diabetes care, engineers have prioritized a low on-body burden while maintaining factory-calibrated precision. During the symposium "Beyond Glucose," experts including Professor David O'Neal and Associate Professor Shannon Lin explored how these integrated systems move beyond mere visibility to provide actionable, real-time insights.

Credentialled Diabetes Educators attending the event emphasized the sensor’s ease of use and the practical utility of its AI-driven spike detection. Clinicians noted that features linking glucose trends to specific meal contexts offer a significant leap in patient education. SIBIONICS intends to expand this ecosystem by integrating continuous ketone monitoring and insulin delivery systems, aiming to shorten the interval between raw data collection and informed medical action.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!